To address this challenge, researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have developed the first nanobody-based inhibitors targeting the Ebola ...

To address this challenge, researchers have developed the first nanobody-based inhibitors targeting the Ebola virus. Ebola virus, one of the deadliest pathogens, has a fatality rate of about 50% ...

George R. Tynan has received research funding from the US Department of Energy and the Office of Fusion Energy Sciences, and has served on numerous advisory panels to DOE and the International ...

This study aims to design and characterize a PD-1-specific nanobody using an integrated computational and experimental approach. Methods: An in silico design strategy was employed, involving ...

From January 13 to 16, Dr. Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, attended the 17th Biotech Showcase conference in San Francisco and the Global Biopharma ...

Indian startups Pranos, Anubal Fusion, and Hylenr are advancing efforts in nuclear fusion by exploring different technological methods. These companies aim to overcome engineering challenges, ...

This binding prevents the virus from utilizing its glycoprotein for attachment and fusion, thereby halting ... These findings support the potential of nanobody technology in addressing viral ...

MoonLake Immunotherapeutics AG New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 ...

KAUST Catalysis Center (KCC), Division of Physical Sciences & Engineering, King Abdullah University of Science and Technology, KAUST, Thuwal 23955, Kingdom of Saudi Arabia ...